The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease.

Mice receiving CD14+ (monocyte) or CD56+ (NK cell) depleted engraftments exhibited an intermediate response to silvestrol treatment (2/4 and 4/5 surviving, respectively) that did not reach statistical significance with this number of animals.

also in 111,027 other papers